Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blood glucose monitor problems to be discussed at March 20-21 FDA panel meeting.

This article was originally published in The Tan Sheet

Executive Summary

BLOOD GLUCOSE MONITOR PROBLEMS SLATED FOR PANEL DISCUSSION at a March 20-21 meeting of FDA's Clinical Chemistry & Clinical Toxicology Devices Panel, according to an upcoming Federal Register notice. FDA is looking for input from the advisory panel and from public presentations by professional organizations, industry and consumers on "mechanisms to help minimize problems associated with" self-monitoring blood glucose systems. The meeting is scheduled to take place at the Holiday Inn in Gaithersburg, Md.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel